Summary & Overview
HCPCS A9610: Xenon xe-129 Hyperpolarized Gas, Diagnostic Dose
HCPCS Level II code A9610 represents a diagnostic dose of Xenon xe-129 hyperpolarized gas used as a contrast agent for advanced pulmonary magnetic resonance imaging. This code identifies a specialized imaging input that enables visualization of lung ventilation and microstructure, supporting diagnosis and management of respiratory disorders. Nationally, the code matters because it tags a high-cost, technology-driven diagnostic supply that may influence utilization patterns in tertiary and specialty imaging centers.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for use of hyperpolarized xenon gas, typical sites of service, and payer coverage landscape. The publication outlines benchmarking areas such as reimbursement coding practice and claim-line reporting for advanced pulmonary MRI contrast, summarizes relevant policy considerations affecting coverage and prior authorization, and highlights clinical scenarios where this diagnostic agent is applied.
The piece also provides practical reference material: code description, common billing considerations, and where to seek additional payer-specific guidance. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code A9610 describes Xenon xe-129 hyperpolarized gas used for diagnostic imaging, reported per study dose. The service involves administration of a hyperpolarized noble gas as a contrast agent to enable specialized pulmonary or respiratory MRI studies that assess lung structure and function.
Service Type: Diagnostic contrast agent for advanced pulmonary imaging
Typical Site of Service: Outpatient imaging centers or hospital outpatient radiology departments
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with unexplained exertional dyspnea and suspected small airways disease is referred for advanced pulmonary imaging using hyperpolarized xenon-129 gas MRI. The patient arrives at an outpatient radiology or specialized pulmonary imaging center after referral from a pulmonologist. Pre-procedure screening confirms no contraindications (e.g., pregnancy, inability to cooperate, severe claustrophobia) and informed consent is obtained. Vital signs and oxygen saturation are recorded; supplemental oxygen is available and staff trained in emergency airway management are present. The patient breathes a controlled inhalation of xenon xe-129 hyperpolarized gas under MRI-safe monitoring during breath-hold maneuvers while the MRI technologist and radiologist coordinate imaging sequences. Typical clinical workflow steps: referral and preauthorization, pre-procedure screening and consent, MRI safety checklist, administration of the hyperpolarized xenon xe-129 study dose, image acquisition by MRI technologist under radiologist supervision, post-procedure recovery and monitoring, image interpretation and reporting to the referring pulmonologist. Typical site of service: outpatient imaging center or hospital outpatient department. Service type: diagnostic imaging using hyperpolarized gas MRI for pulmonary gas-exchange and ventilation-perfusion assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |